



Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology.

Catherine Pavoine, Françoise Pecker

► To cite this version:

Catherine Pavoine, Françoise Pecker. Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology.: Sphingomyelinases in cardiovascular pathophysiology. Cardiovascular Research, 2009, 82 (2), pp.175-83. 10.1093/cvr/cvp030 . inserm-00371935

HAL Id: inserm-00371935

<https://inserm.hal.science/inserm-00371935>

Submitted on 25 Feb 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Table. Sphingomyelinases in cardiovascular physiology and pathophysiology

Group	Acid sphingomyelinases		Neutral sphingomyelinases	
Gene	<i>Smpd1</i> ^{24,25}	<i>Smpd2</i> ²⁹	<i>Smpd3</i> ³⁰	<i>Smpd4</i> ¹²
Protein	L-ASMase ⁵²	S-ASMase ⁵²	NSMase1 ²⁹	NSMase2 ³⁰
Biochemical properties	Zn ²⁺ , pH 5 optimum ^{4,9,11,22}		Mg ²⁺ , pH 7.4 optimum ^{4,9,29}	
Subcellular compartment	Lysosomes/ endosomes ^{9,53} , Outer plasma membrane ⁵⁶	Secreted ^{9,11,26,52,54}	ER ²⁹	Golgi ^{30,33} Plasma membrane ²
Cellular expression	Ubiquitous ^{23,28,34} with high expression in EC ^{54,55}		Ubiquitous ²⁷	Ubiquitous ³³
Biological activator	I/R insult (CM) ⁴⁶⁻⁴⁸ Ischemic preconditioning (CM) ^{47,49} Fas/ FasL (EC) ⁵⁹⁻⁶⁰ MR1 agonist (VSMC) ⁶¹ Oxidized phospholipids (VSMC) ⁶⁷ ROS ⁷⁶⁻⁷⁸	IFN gamma (EC) ⁵⁵ IL1-beta (EC) ⁵⁵	TNF, ROS, oxLDL (VSMC) ⁹⁵⁻⁹⁷	TNF (CM, VSMC) ^{83-84,95} IL1-beta (CM) ⁹⁵ ApoC1HDL, oxLDL (VSMC) ⁹³⁻⁹⁴ Hypoxia/ reoxygenation (CM) ¹⁰⁴
Biological effect	Lysosomal sphingolipid storage (all cell types) ²³ Post-IR cell death, contractile dysfunction (CM) ⁴⁶⁻⁴⁹ Vascular tone constriction (EC, VSMC) ⁵⁹⁻⁶¹ Oxidized phospholipids -induced apoptosis (VSMC) ⁶⁷		Growth ³³ TNF-, ROS-, oxLDL-induced proliferation (VSMC) ⁹⁵⁻⁹⁷	TNF-, IL-1, hypoxia/reoxygenation-induced apoptosis (CM) ^{83-85, 104,109} TNF-, IL1-beta-induced negative inotropic effect (CM) ^{84,112,85} ApoC1HDL-induced apoptosis (VSMC) ⁹³ OxLDL-, TNF-induced proliferation (VSMC) ⁹⁴⁻⁹⁵ Vasorelaxation (EC) ^{14,100-101}
Pathophysiology	Niemann-Pick disease (<i>smpd1</i> null mutation) ^{23,35} Atherosclerosis ^{59-61,68}	Atherosclerosis ^{62-66,68} Heart failure ^{79,81}	Atherosclerosis ^{93,95-97}	
Biological inhibitor	Oxidized glutathione ⁹		Oxidized/ reduced glutathione ^{29,88-92}	
Pharmacological inhibitor	D609 ⁴⁶ , Desipramine ^{48-49,81} , NB6 ¹¹⁹ , L-carnitine ¹²⁰		Scyphostatin ^{14,122} , GW4869 ^{101,123}	
Pharmacological activator	Doxorubicine ¹²⁰			
Therapeutical target	Atherosclerosis ⁵⁹⁻⁶⁸ Pre/post conditioning ^{46,48}		Atherosclerosis ⁹³⁻⁹⁷	
Diagnostic tool	Heart failure ^{79,81}		Heart failure ⁹¹⁻⁹²	

VSMC, vascular smooth muscle cells; EC, endothelial cells; CM, cardiomyocytes; ER, endoplasmic reticulum; I/R, ischemia/ reperfusion; ROS, reactive oxygen species.